JP2009541386A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541386A5
JP2009541386A5 JP2009516964A JP2009516964A JP2009541386A5 JP 2009541386 A5 JP2009541386 A5 JP 2009541386A5 JP 2009516964 A JP2009516964 A JP 2009516964A JP 2009516964 A JP2009516964 A JP 2009516964A JP 2009541386 A5 JP2009541386 A5 JP 2009541386A5
Authority
JP
Japan
Prior art keywords
alkyl
acid
alkoxy
substituted
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009516964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541386A (ja
Filing date
Publication date
Priority claimed from GBGB0612721.1A external-priority patent/GB0612721D0/en
Application filed filed Critical
Publication of JP2009541386A publication Critical patent/JP2009541386A/ja
Publication of JP2009541386A5 publication Critical patent/JP2009541386A5/ja
Pending legal-status Critical Current

Links

JP2009516964A 2006-06-27 2007-06-25 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター Pending JP2009541386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds
PCT/EP2007/005597 WO2008000419A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013076909A Division JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Publications (2)

Publication Number Publication Date
JP2009541386A JP2009541386A (ja) 2009-11-26
JP2009541386A5 true JP2009541386A5 (https=) 2010-08-26

Family

ID=36888144

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2009516964A Pending JP2009541386A (ja) 2006-06-27 2007-06-25 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2013076909A Pending JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2016087703A Withdrawn JP2016185957A (ja) 2006-06-27 2016-04-26 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2018021389A Withdrawn JP2018109018A (ja) 2006-06-27 2018-02-08 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2019089217A Active JP6931019B2 (ja) 2006-06-27 2019-05-09 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2020176666A Active JP7258832B2 (ja) 2006-06-27 2020-10-21 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2023061697A Pending JP2023098949A (ja) 2006-06-27 2023-04-05 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2024172795A Pending JP2025016462A (ja) 2006-06-27 2024-10-01 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013076909A Pending JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2016087703A Withdrawn JP2016185957A (ja) 2006-06-27 2016-04-26 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2018021389A Withdrawn JP2018109018A (ja) 2006-06-27 2018-02-08 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2019089217A Active JP6931019B2 (ja) 2006-06-27 2019-05-09 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2020176666A Active JP7258832B2 (ja) 2006-06-27 2020-10-21 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2023061697A Pending JP2023098949A (ja) 2006-06-27 2023-04-05 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2024172795A Pending JP2025016462A (ja) 2006-06-27 2024-10-01 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Country Status (20)

Country Link
US (3) US20100168078A1 (https=)
EP (4) EP2037906A1 (https=)
JP (8) JP2009541386A (https=)
KR (6) KR20140069178A (https=)
CN (2) CN103550195A (https=)
AU (7) AU2007264031C1 (https=)
BR (1) BRPI0713985A2 (https=)
CA (1) CA2653569C (https=)
DE (1) DE15177166T1 (https=)
DK (1) DK2959894T3 (https=)
ES (1) ES2887042T3 (https=)
GB (1) GB0612721D0 (https=)
HU (1) HUE059922T4 (https=)
LT (1) LT2959894T (https=)
MX (3) MX2008016133A (https=)
PL (1) PL2959894T3 (https=)
PT (1) PT2959894T (https=)
RU (1) RU2617502C2 (https=)
SI (1) SI2959894T1 (https=)
WO (1) WO2008000419A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2707576T3 (es) * 2007-05-04 2019-04-04 Novartis Ag Uso de modulador del receptor S1P
KR20110020928A (ko) * 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
ES2526119T3 (es) 2008-08-18 2015-01-07 Novartis Ag Derivado de azetidina para el tratamiento de neuropatías periféricas
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
CN102256942B (zh) * 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
PT2676953T (pt) * 2008-12-18 2017-06-29 Novartis Ag Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
CA2747558A1 (en) * 2008-12-18 2010-07-15 Novartis Ag New salts
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
JP5939158B2 (ja) * 2009-11-24 2016-06-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 治療的有用性を有する受容体調節物質としての新規化合物
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
PH12014500854A1 (en) * 2011-10-21 2021-08-09 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
EP2830338A4 (en) * 2012-03-23 2015-12-30 Nec Corp SUBSCRIBER SERVER, MONITOR SERVER, MOBILE TERMINAL, ASSOCIATED METHOD AND COMPUTER READABLE MEDIUM
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
AU2022328858A1 (en) * 2021-08-20 2024-02-22 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
WO2000059509A1 (en) 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
WO2002006268A1 (en) 2000-07-13 2002-01-24 Sankyo Company, Limited Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
EP1511473B8 (en) * 2002-05-27 2013-07-24 Novartis AG Bis-aromatic alkanols
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ES2558761T3 (es) * 2003-05-19 2016-02-08 Novartis Ag Compuestos y composiciones inmunosupresores
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
EP1753442A2 (en) * 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
US7972596B2 (en) * 2004-11-18 2011-07-05 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
KR20140095109A (ko) * 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
BRPI0518105A (pt) * 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Similar Documents

Publication Publication Date Title
JP2009541386A5 (https=)
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
JP2014515013A5 (https=)
EP2592070A3 (en) Tetrazole-substituted arylamides
JP2009534471A5 (https=)
WO2009087212A3 (en) Pyridine derivatives
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
CY1112826T1 (el) [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες
NO20054206L (no) Bifenylderivater
JP2011512412A5 (https=)
JP2007523051A5 (https=)
JP2012530758A5 (https=)
ZA200710145B (en) Method for the production of 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl-benzofuran-2-carboxamide
WO2007127196A3 (en) DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2010520214A5 (https=)
JP2005522432A5 (https=)
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
EA201001645A1 (ru) Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
JP2017509611A5 (https=)
CL2007002349A1 (es) Compuestos derivados de pirazolo[3,4-b]piridina; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de una enfermedad inflamatoria y/o alergica, tal como epoc, asma y rinitis.
JP2009501745A5 (https=)
JP2012511558A5 (https=)
WO2009145816A3 (en) Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
JP2009505973A5 (https=)